NCT00937937 2026-03-18
Dinaciclib in Treating Patients With Stage IV Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT01515176 2018-03-15
Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01026324 2017-04-04
Dinaciclib in Treating Patients With Stage III-IV Melanoma
National Cancer Institute (NCI)
Phase 1/2 Terminated